Jason Fontenot PhD

Jason Fontenot is the Chief Scientific Officer of Stylus Medicine. Before Stylus, Jason served as CSO at Sangamo Therapeutics. Before Sangamo, he served as SO of Immusoft, and previously as Head of Exploratory Research at Juno Therapeutics. Before Juno, Jason served as a group leader in Immunology Research at Biogen. Jason has led and contributed to the successful advancement of numerous small molecule, biologic, and cell & gene therapy drug development programs. These efforts have resulted in multiple investigational new drug (IND) filings, including programs currently in clinical development and two FDA-approved therapies - the CD19-target CAR T therapy, Breyanzi, for the treatment of B-cell lymphoma and the CD25-target monoclonal antibody Zinbryta for the treatment of multiple sclerosis.

Jason's academic research focused on lineage specification in the immune system. His discoveries defining the role of FoxP3 in regulatory T cell biology established the molecular basis for dominant immune tolerance and produced some of the most highly cited immunology publications of the last two decades. This work has had a lasting impact on the field of immunology and shaped the direction of pharmaceutical R&D in autoimmunity, transplantation, and cancer immunotherapy. Jason holds a Ph.D. in Immunology from the University of Washington in Seattle, Washington, and held postdoctoral fellowships at the University of Washington and Rockefeller University.